Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer

Acta Medica Okayama

Volumn 65, Issue 4, 2011, Pages 231-237

  Shien, Tadahiko ^a   Doihara, Hiroyoshi ^a   Nishiyama, Keiko ^a   Masuda, Hiroko ^a   Nogami, Tomohiro ^a   Ikeda, Hirokuni ^a   Taira, Naruto ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Metastatic breast cancer; Metronomic

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST TUMOR; DISEASE COURSE; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES;

EID: 80052684391     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Program NCICTE: Common toxicity Criteria, version 2.0. (April 30, 1999).
2. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluo-ropyrimidine carbamate, capecitabine, which generates 5-fluorou-racil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer (1998) 34: 1274-1281.
3. Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, llegbodu D, Asmar L and O'Shaughnessy JA: Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer (2007) 7: 465-470.
4. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M and Luck HJ: Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol (2003) 14: 1227-1233.
5. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z and Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer (2004) 40: 536-542.
6. Yamamoto Y, Toi M and Tominaga T: Prediction of the effect of 5' -deoxy-5-fluorouridine by the status of angiogenic enzyme thymi-dine phosphorylase expression in recurrent breast cancer patients. Oncology Reports (1996) 3: 863-865.
7. Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M and Kasumi F: The potential for oral com bination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Br J Cancer (2003)89: 1627-1632.
8. Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y and Sakamoto J: Dose-finding phase I and pharmacoki-netic study of capecitabine (xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or meta static breast cancer. Oncology-Basel (2007) 72: 330-337.
9. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H and Tanaka Y: Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. International Journal of Cancer (1999) 83: 127-134.
10. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res (1998) 4: 1013-1019.
11. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S and Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol (2002) 20: 2812-2823.
12. Chan S, Romieu G, Huober J, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Carrasco E, Thareau VA and Fumoleau P: Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients. J Clin Oncol (2009) 27: 1753-1760.
13. Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE and Marcom PK: Capecitabine plus paclitaxel as front line combination therapy for metastatic breast cancer: A multi-center phase II study. J Clin Oncol (2004) 22: 2321-2327.
14. Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Baron MG, Villman K, Soderberg M, Ahlgren J, Casinello J, Regueiro P and Murias A: Phase II study of capecit abine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Brit J Cancer (2004)90: 1740-1746.
15. Harvey VJ, Sharpies K, Isaacs R, Jameson MB, Jeffery M, McLaren B, Pollald S, Riley G, Simpson A, Findeay MP: A ran domized phase II study comparing capecitabine (C) with C plus oral cyclophosphamide (CCy) in patients (pts) with advanced breast cancer (BC). J Clin Oncol (2008) 26 (Suppl.).
16. Ohno S, Mitsuyama S, Tamura K, Nishimura R, Tanaka M, Hamada Y, Kuroki S and Grp KBCS: Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res (2007) 27: 1009-1013.
17. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumours. Nature (2000) 406: 747-752.
18. Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol (2007) 8: 235-244.
19. Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S and Kerbel RS: Anti-angiogenic treatment of breast cancer using met ronomic low-dose chemotherapy. Breast (2005) 14: 466-479.
20. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L and Berruti A: Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol (2006) 24: 3623-3628.
21. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E and Colleoni M: Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. J Clin Oncol (2008) 26: 4899-4905.
22. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E and Colleoni M: Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. Bmc Cancer (2006) 6: 225.
23. KamatAA, Kim TJ, Landen CN, LuCH, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV,Jaffe RB, Coleman RL and Sood AK: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 67: 281-288.